<DOC>
	<DOCNO>NCT00865410</DOCNO>
	<brief_summary>The purpose study compare rate extent absorption Bupropion HCl extended-release tablet ( test ) Wellbutrin SR extended-release tablet ( reference ) single , one-tablet ( 150 mg ) dose fast subject .</brief_summary>
	<brief_title>A Relative Bioavailability Study Bupropion Extended-Released 150 mg Tablets Under Fasting Conditions</brief_title>
	<detailed_description>Study Type : Interventional Study Design : Randomized , 2-period , 2-sequence , crossover design . Official Title : A Randomized , Single Dose Two -Way Crossover Relative Bioavailability Study Bupropion Extended-Released Tablets Formulation Fasted , Normal , Healthy Subjects . Further study detail provide Actavis Elizabeth LLC : Primary Outcome Measures : Rate Extend Absorption</detailed_description>
	<mesh_term>Bupropion</mesh_term>
	<criteria>Is individual healthy , normal adult man volunteer participate ? Is 1845 year age , inclusive ? Is BMI â‰¤30 ? Is consider reliable capable understanding responsibility role study ? Has provide write informed consent ? A answer question indicate individual ineligible enrollment Does individual history allergy hypersensitivity bupropion , milk egg ? Does smoke 25 cigarettes/day ? Is unable refrain smoking period begin two hour end four hour study drug administration ? Does history seizure , cranial trauma , predisposition seizure ? Does clinically significant laboratory abnormality would interfere conduct interpretation study jeopardize safety ? Does significant history clinical evidence autoimmune , cardiovascular , gastrointestinal , hematological , hematopoietic , hepatic , neurological , ongoing infection , pancreatic , renal disease , condition surgery would interfere conduct interpretation study jeopardize safety ? Does serious psychological illness ? Does significant history ( within past six month ) clinical evidence alcohol drug abuse ? Does positive urine drug screen saliva alcohol screen , positive HIVl , hepatitis B C screen ? Is unable refrain use alcohol xanthinecontaining food beverage period begin 24 48 hour , respectively , prior study drug administration end last blood sample take ? Has use prescription drug 14day period prior study initiation ( except topical product without systemic absorption ) , OTC drug 72hour period precede study initiation ? Is unable refrain use concomitant medication study ? Has donate lose blood , participate clinical study involve withdrawal large volume blood ( 480 mL ) , six week period precede study initiation ? Has donate plasma two week period precede study initiation ? Has receive investigational drug 30 day period precede study initiation ? A yes answer question indicate individual ineligible enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Bupropion</keyword>
	<keyword>Healthy subject</keyword>
</DOC>